SOURCE: The Bedford Report

The Bedford Report

June 17, 2011 08:16 ET

XOMA and BioSante Present Promising Pipelines

The Bedford Report Provides Investment Research on XOMA & BioSante

NEW YORK, NY--(Marketwire - Jun 17, 2011) - Cancer is projected to become the leading cause of death worldwide this year by the World Health Organisation and has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides stock analysis on XOMA Ltd. (NASDAQ: XOMA) and BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). Access to the full company reports can be found at:

www.bedfordreport.com/XOMA

www.bedfordreport.com/BPAX

Cancer medication is also an inherently risky sector. Earlier this year Reuters published research from BioMed Tracker and BIO, which claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards, recommending that sponsors generally be required to conduct randomized trials rather than single-arm studies, and that there be more extensive postmarketing studies to confirm clinical benefit.

The Bedford Report releases investment research on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Currently, Biosante Cancer Vaccines are in various Phase I and Phase II cancer clinical trials and may represent the widest portfolio of cancer vaccines in development. The company believes that "cancer vaccines are an increasingly exciting option for cancer treatment, especially after the FDA approval of Provenge for the treatment of prostate cancer in April 2010."

XOMA engages in the discovery, development, and manufacture of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. The company has an investigational drug, HCD122, in its pipeline which XOMA says "has a dual mechanism of action that involves blocking tumor cell growth and survival signals while recruiting immune effector cells to kill tumor cells through a process known as antibody-dependent cellular cytotoxicity."

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information